SUMMARY Eighteen patients with diffuse varioliform gastritis were enrolled in a double-blind, placebo-controlled trial of sodium cromoglycate, 200 mg a day, and sodium cromoglycate, 400 mg a day, for 28 days. An additional six patients were treated with cimetidine 1 g daily for 28 days. The improvement in terms of patient's subjective assessment, endoscopic assessment, and immunohistochemical measurements of IgE cells in the mucosa was significantly greater in patients given sodium cromoglycate than that in those given cimetidine or placebo. The results provide evidence that type 1 hypersensitivity plays some part in the pathogenesis of varioliform gastritis. It is, therefore, important to differentiate this condition from other types of gastritis, as treatment with sodium cromoglycate appears to be effective.
Diffuse varioliform gastritis is an uncommon form of gastric mucosal inflammation, the incidence in this unit being approximately 0.5% of over 20 000 upper endoscopies. It is an inflammatory condition affecting mainly the body of the stomach, and consists of swollen, congested rugae and scattered erosions situated on discrete mucosal elevations. These 'varioliform' lesions are commonly seen in the antrum, but diffuse varioliform gastritis should only be diagnosed when the mucosa of the fundus and body is affected, the rugae are enlarged, and consistent histological abnormalities are found. Synonyms of this condition include 'octopus sucker gastritis" and gastritis with complete erosions.2
In a review of 90 cases seen in Lyon over a period of eight years,3 the clinical features were as follows: epigastric pain (70%, simulating peptic ulcer in 30%), anorexia and nausea with occasional vomiting (31%), weight loss (>5 kg in 34%, >10 kg in 20%), anaemia due to occult blood loss (3.3%), and overt bleeding (3.3%). Oedema due to hypoproteinaemia, 5 August 1981 also known to occur in this condition,4 was seen in two cases.
In 10 of the 90 patients the lesions occurred acutely after administration of anti-inflammatory drugs (aspirin, indomethacin, phenylbutazone, salazopyrin), but the symptoms were chronic with periods of remission in most patients. Fifty-two patients were followed up for from one to five years. In that time 15 healed spontaneously, 28 improved, eight were unchanged, and one deteriorated. The typical 'varioliform' lesions and hypertrophic gastric folds could be recognised by double-contrast radiology (Fig. 1 ) or at endoscopy (Fig. 2) . Basal and stimulated acid outputs (10 patients) and fasting plasma gastrin (nine patients) were normal.
Histologically the disease is characterised by superficial mucosal ulceration, a chronic inflammatory infiltrate in the lamina propria and enlargement of the gastric glands without loss of specialised cells. The changes seen therefore allow differentiation between this condition and Menetrier's disease, hypertrophic hypersecretory gastropathy, and eosinophilic gastritis, all of which may present similarly, can cause a protein losing state, and may have similar macroscopic appearances.
Histological analysis of the immunoglobulincontaining cell population in the inflammatory 348 infiltrate showed a high proportion of IgE-containing cells.3 Raised serum levels of IgE were found in four of 12 patients studied. This suggests that immediate hypersensitivity may be involved in the pathogenesis of the disease, and, encouraged by the results of a pilot study4 reported elsewhere, we therefore undertook a randomised, placebo-controlled, double-blind trial of the mast cell stabilising agent sodium cromoglycate (Nalcrom). An uncontrolled comparison with the histamine H2 receptor antagonist cimetidine (Tagamet) was also made.
Methods

PATIENTS
A total of 24 newly presenting patients (17 males, seven females) were studied after the diagnosis of varioliform gastritis had been established endoscopically (Olympus GIF-K endoscope). Biopsies were taken from the fundus and antrum on each occasion for histology and immunohistochemistry. The first 18 patients were randomly allocated to one of three groups: sodium cromoglycate 200 mg or 400 mg daily, or placebo. All three treatments were taken as one ampoule of clear, tasteless liquid before meals and at bedtime for 28 days, the contents of the ampoules being unknown to both the patient and the doctor making the assessments. Six patients were allocated to each group, and the details of the three groups are given in Table 1 . No difference between the groups occurred with respect to age, sex, length of history, or incidence of other allergic diseases. Twelve of the 24 patients described previous allergies: atopic eczema (six patients), asthma (three patients), urticaria (two patients), and one patient had both asthma and eczema. Raised serum levels of IgE were found in 10 subjects (range 266-1700 ,g/l, normal range <250 ,g/l), and these patients were evenly distributed throughout the three groups. Eosinophilia was observed in six patients, no difference being observed between the respective groups.
An additional six patients were treated with cimetidine 1 g daily for 28 days, no attempt being made to 'blind' this part of the study.
Clinical and endoscopic assessment including biopsies were made immediately before and after the treatment period, and patients were asked to rate the result as complete cure, considerable improvement, or failure. A similar rating systems was used by the endoscopist.
Immunohistochemical measurements of the numbers of plasma cells of each immunoglobulin class were made using a previously described method. have an allergic basis, or at least that type 1 hypersenTreatment with placebo produced no change in sitivity plays some part in the pathogenesis of the either total or Ig class-specific plasma cell numbers. disease.3 4 No specific allergens have, as yet, been Sodium cromoglycate 200 mg daily resulted in a signi-identified, but the allergic nature of the disease is ficant change in IgE cell numbers in the fundus suggested by the typical relapsing clinical course, the (p<0.05) and in the antrum (P<0-05). Sodium cro-increased incidence of other allergic diseases in these moglycate 400 mg daily also produced a significant patients as compared with the normal population, the fall in IgE cell numbers in both antrum and fundus high incidence of eosinophilia and raised serum IgE (p<0-01) and a significant fall in IgG cells in the levels, and finally the demonstration of large numantrum (P<0.05), while the effects of cimetidine bers of IgE-containing cells in the gastric mucosa.
were not significant (all statistics performed using The results of the present study lend additional supStudent's t test for paired data).
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